One limitation to our study is that we have considered resistance in single trastuzumab treatment models, when the current therapeutic protocol establishes first-line treatment with trastuzumab in combination with pertuzumab (a second monoclonal antibody) for HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.